How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,127 results for

Stereotactic Body Radiation Therapy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines Effective Date: January 1, 2018 Proprietary Date of Origin: 05/14 (...) , limitations and safety aspects of image-guided therapy. IGRT is an integral part of the delivery of highly conformal treatments such as intensity modulated radiation therapy (IMRT), stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). Recognition of this fact has resulted in changes to the current procedural terminology (CPT) definitions such that the technical aspect of IGR T is now bundled with IMRT delivery. Similarly, image guidance procedures have always been bundled for SBRT

2018 AIM Specialty Health

2. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer

Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer . Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Prostate cancer is expected to be the most common cancer diagnosed among men in the United States in 2016, comprising nearly

2017 Health Technology Assessment (HTA) Database.

3. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer

Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer . Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Prostate cancer is expected to be the most common cancer diagnosed among men in the United States in 2016, comprising nearly

2017 Health Technology Assessment (HTA) Database.

4. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline.

Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. | National Guideline Clearinghouse success fail JUN 10 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue (...) NGC:011261 2017 Sep-Oct NEATS Assessment Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, Lally BE, Latzka K, Lo SS, Moghanaki D, Movsas B, Rimner A, Roach M, Rodrigues G, Shirvani SM, Simone CB II, Timmerman R, Daly ME. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence

2017 National Guideline Clearinghouse (partial archive)

5. Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death. (PubMed)

Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death. To review the radiobiological mechanisms of SBRT and SRS.We reviewed previous reports and recent observations on the effects of high-dose irradiation on tumor cell survival, tumor vasculature and anti-tumor immunity. We then assessed the potential implications of these biological changes associated with SBRT and SRS.Irradiation with doses higher than approximately

2019 Biology and Physics

6. Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases (PubMed)

Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases Single-fraction radiation surgery for spine metastases is highly effective. However, a high rate (20-39%) of vertebral body fracture (VBF) has been associated with large, single-fraction doses. We report our experience using multifraction stereotactic body radiation therapy (SBRT).All patients who were treated with multifraction SBRT for spine metastases at our institution

Full Text available with Trip Pro

2018 Advances in radiation oncology

7. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched (...) and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes.A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts.Thirty-two studies were identified in the systematic review, and 23 were selected

2019 EvidenceUpdates

8. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. (PubMed)

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. To report the feasibility of conducting a randomized study to compare the toxicity and efficacy of stereotactic body radiation therapy (SBRT) versus stereotactic body proton therapy (SBPT) for high-risk, medically inoperable, early-stage non-small cell lung cancer (NSCLC).Patients with medically inoperable NSCLC with high-risk (...) features (centrally located or <5 cm T3 tumor or isolated lung parenchymal recurrences) were randomly assigned to SBRT or SBPT. Radiation dose was 50 Gy(relative biological effectiveness [RBE]) in 4 12.5-Gy(RBE) fractions prescribed to the planning target volume. Stereotactic body radiation therapy was given using 3-dimensional conformal radiation therapy or intensity modulated radiation therapy, and SBPT was given using passive scattering. Consistency in patient setup was ensured with on-board cone

2018 Biology and Physics

9. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma (PubMed)

Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma Locally recurrent pancreatic cancer after prior radiotherapy is a therapeutic challenge with limited treatment options. This study examines the safety and efficacy of stereotactic body radiation therapy (SBRT) for locally recurrent pancreatic adenocarcinoma after prior conventional fractionation radiotherapy (CRT).Outcomes from all patients

Full Text available with Trip Pro

2017 Advances in radiation oncology

10. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy (PubMed)

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy For patients with localized pancreatic cancer (PC) with vascular involvement, prediction of resectability is critical to define optimal treatment. However, the current definitions of borderline resectable (BR) and locally advanced (LA) disease leave considerable heterogeneity in outcomes within these classifications. Moreover, factors (...) beyond vascular involvement likely affect the ability to undergo resection. Herein, we share our experience developing a model that incorporates detailed radiologic, patient, and treatment factors to predict surgical resectability in patients with BR and LA PC who undergo stereotactic body radiation therapy (SBRT).Patients with BR or LA PC who were treated with SBRT between 2010 and 2016 were included. The primary endpoint was margin negative resection, and predictors included age, sex, race

Full Text available with Trip Pro

2018 Advances in radiation oncology

11. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution (PubMed)

Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution Purpose Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non-small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated

Full Text available with Trip Pro

2018 Journal of global oncology

12. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies (PubMed)

Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies The role of external beam radiation therapy (EBRT) in the management of upper gastrointestinal malignancies is constantly evolving. As radiation therapy techniques improve and are able to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation can be applied to a wider range of clinical scenarios. Stereotactic body radiation therapy (SBRT) allows a high dose of radiation to be delivered (...) to a highly conformal treatment volume in a short amount of time. Another potential advantage of SBRT is its ability to increase tumor immunogenicity, while also having less of an immunosuppressive effect on the patient, as compared to conventionally fractionated radiation therapy. In so doing, SBRT may potentiate the effects of immune therapy when the two treatments are combined, thus improving therapeutic outcomes. This article provides an overview of the role of SBRT in the management of upper

Full Text available with Trip Pro

2018 Biomedicines

13. Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity (PubMed)

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity This study aimed to report on our institutional experience in the use of stereotactic body radiation therapy (SBRT) for the treatment of adrenal gland metastases. Specifically, we examined the outcomes and toxicity from this treatment modality on adjacent organs at risk.Data were retrieved from patients with adrenal metastases who were treated with SBRT between 2008 and 2017. Patients with primary adrenal

Full Text available with Trip Pro

2018 Advances in radiation oncology

14. Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy (PubMed)

Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy Radiographic lung changes after stereotactic body radiation therapy (SBRT) vary widely between patients. Standardized descriptions of acute (≤6 months after treatment) and late (>6 months after treatment) benign lung changes have been proposed but the reliable application of these classification systems has not been demonstrated. Herein, we examine the interobserver reliability

Full Text available with Trip Pro

2018 Advances in radiation oncology

15. Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. (PubMed)

Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. To appraise the ability of a radiomics signature to predict clinical outcome after stereotactic body radiation therapy (SBRT) for pancreas carcinoma.A cohort of 100 patients was included in this retrospective, single institution analysis. Radiomics texture features were extracted from computed tomography (CT) images obtained for the clinical

Full Text available with Trip Pro

2019 PLoS ONE

16. Stereotactic body radiation therapy for locally advanced pancreatic cancer. (PubMed)

Stereotactic body radiation therapy for locally advanced pancreatic cancer. Stereotactic body radiation therapy (SBRT) is a promising treatment modality for locally advanced pancreatic cancer (LAPC). We evaluated the clinical outcomes of SBRT in patients with LAPC.We retrospectively analyzed the medical records of patients with LAPC who underwent SBRT at our institution between April 2011 and July 2016. Fiducial markers were implanted using endoscopic ultrasound guidance one week prior to 4 (...) -dimensional computed tomography (CT) simulation and daily cone beam CT was used for image guidance. Patients received volumetric modulated arc therapy or intensity modulated radiotherapy using respiratory gating technique. A median dose of 28 Gy (range, 24-36 Gy) was given over four consecutive fractions delivered within one week. Survival outcomes including freedom from local disease progression (FFLP), progression-free survival (PFS), and overall survival (OS) were analyzed. Acute and late toxicities

Full Text available with Trip Pro

2019 PLoS ONE

17. Differences in United States insurance payer policies and American Society for Radiation Oncology's (ASTRO) model policy on stereotactic body radiation therapy (SBRT). (PubMed)

Differences in United States insurance payer policies and American Society for Radiation Oncology's (ASTRO) model policy on stereotactic body radiation therapy (SBRT). Insurance payers in the United States vary in the indications for which they consider stereotactic body radiation therapy (SBRT) "medically necessary." We compared changes in policies after the last update to the American Society for Radiation Oncology's (ASTRO) SBRT model policy.We identified 77 payers with SBRT policies in 2015

2019 Biology and Physics

18. Evaluating risk factors of radiation pneumonitis after stereotactic body radiation therapy in lung tumor: Meta-analysis of 9 observational studies. (PubMed)

Evaluating risk factors of radiation pneumonitis after stereotactic body radiation therapy in lung tumor: Meta-analysis of 9 observational studies. In this study, we assessed the association of SBRT (stereotactic body radiotherapy) dose and volume with radiation pneumonitis (RP) risk in lung tumor.Relevant articles were identified up to April 2018, using following databases; Medline, EMBASE, Cochrane Library, and China National Knowledge Infrastructure (CNKI). The pooled OR (odds ratio) with 95

Full Text available with Trip Pro

2018 PLoS ONE

19. Dosimetric evaluation of respiratory gated volumetric modulated arc therapy for lung stereotactic body radiation therapy using 3D printing technology. (PubMed)

Dosimetric evaluation of respiratory gated volumetric modulated arc therapy for lung stereotactic body radiation therapy using 3D printing technology. This study aimed to evaluate the dosimetric accuracy of respiratory gated volumetric modulated arc therapy (VMAT) for lung stereotactic body radiation therapy (SBRT) under simulation conditions similar to the actual clinical situation using patient-specific lung phantoms and realistic target movements.Six heterogeneous lung phantoms were

Full Text available with Trip Pro

2018 PLoS ONE

20. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. (PubMed)

Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. To compare outcomes in patients receiving neoadjuvant stereotactic body radiation therapy (SBRT) with those receiving intensity-modulated radiation therapy (IMRT) for pancreatic adenocarcinoma.We analyzed patients receiving neoadjuvant SBRT for borderline resectable (BRPC) and locally advanced pancreatic cancer

2018 Journal of Surgical Oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>